All Activities

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.

Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information

Featured Activity

This activity will review the latest PK recommendations for Factor VIII and IX replacement and how to use and interpret PK parameters to assess treatment plans.

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.


Standardization in Health-System Pharmacy: Practical Solutions to Reduce Risk of IV Compounding Errors

Activity Downloads

To Participate

To participate in this continuing education activity:

  1. Review the activity description and objectives.
  2. View the activity.
  3. Complete the online post-test and activity evaluation.

Note: If you attended the live CE activity AND received CE credit (i.e. a pharmacist CE statement of credit with ACPE UAN 0221-0000-18-122-L05-P), you are NOT allowed to also receive credit for this home-study on-demand web activity.

Activity Description

No medication errors and zero patient harm are goals of all pharmacists. This activity will explore the importance of pharmacy standardization and the role pharmacy leadership needs to take to minimize error potential in sterile compounding. Standardization strategies such as ASHP’s “Standardize 4 Safety” initiative program will be discussed as well as the FDA requirements for 503A versus 503B sterile compounding operations in health-systems.

Learning Objectives

The target audience for this activity includes pharmacy administrators, compounding pharmacists, and pharmacists in health-system settings. At the completion of this symposium, the participant will be able to:

  • Describe the role of pharmacy leadership in ensuring IV medication safety.
  • List pharmacy standardization strategies to improve IV medication safety.
  • Identify guidelines, policies and safety initiatives for standardization and work process intended to reduce errors, including the ASHP “Standardize 4 Safety Initiative”.
  • Describe the impact of IV compounding errors from the patient/family and health provider viewpoints.
  • Outline the impact regulatory systems and changes may have on sterile compounding practices, including differences between 503A and 503B requirements.


Chair: Christina Michalek, BSc Pharm, RPh, FASHP
Medication Safety Specialist
Institute for Safe Medication Practices
Horsham, Pennsylvania

Christopher S. Jerry
President and CEO
The Emily Jerry Foundation
Cleveland, Ohio

Deborah A. Pasko, PharmD, MHA
Director, Medication Safety & Quality
Center on Medication Safety and Quality
American Society of Health-System Pharmacists
Bethesda, Maryland

Kevin Hansen, PharmD, MS, BCPS
Assistant Director of Pharmacy
Cone Health, Moses H. Cone Memorial Hospital
Greensboro, North Carolina

CE Accreditation

Release Date: 6-5-2018
Expiration Date: 6-5-2019


ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-18-122-H05-P has been assigned to this home study knowledge-based activity (initial release date 6-5-2018). This activity is approved for 1.5 contact hours (0.15 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at, and proof of completion will be posted in NABP CPE Monitor profiles.


It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Dr. Hansen has no relevant commercial or financial relationships to disclose. Mr. Jerry is a Consultant for ARxIUM. Ms. Michalek has no relevant commercial or financial relationships to disclose. Dr. Pasko has no relevant commercial or financial relationships to disclose. A portion of grant funds received by ProCE from PharMEDium Services, LLC will be used to compensate the faculty for this presentation.

Please note: The opinions expressed in this activity should not be construed as those of the CE provider. The information and views presented in this activity are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include the use of drugs and/or devices for unlabeled indications, which should be considered experimental. Participants are advised to consult manufacturer product information and the professional literature, and use professional judgment in applying the presented information in patient-care activities.


This activity is provided by ProCE, Inc. and is supported by an educational grant from PharMEDium Services, LLC.


The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Download Handout